Steward Partners Investment Advisory’s Actinium Pharmaceuticals ATNM Stock Holding History

Steward Partners Investment Advisory’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.96K	Sell	2,000 -166	-8%	-$192	﹤0.01%	4242
2026 Q1	$2.16K	Hold	2,166	–	–	﹤0.01%	4035
2025 Q4	$2.95K	Hold	2,166	–	–	﹤0.01%	3853
2025 Q3	$3.47K	Buy	2,166 +166	+8%	+$270	﹤0.01%	3768
2025 Q2	$2.8K	Hold	2,000	–	–	﹤0.01%	3660
2025 Q1	$3.22K	Hold	2,000	–	–	﹤0.01%	3515
2024 Q4	$2.52K	Hold	2,000	–	–	﹤0.01%	3578
2024 Q3	$3.76K	Buy	+2,000	New	+$7.9K	﹤0.01%	3274
2024 Q2	–	Sell	-100	Closed	-$783	–	3613
2024 Q1	$783	Hold	100	–	–	﹤0.01%	3394
2023 Q4	$508	Hold	100	–	–	﹤0.01%	3359
2023 Q3	$592	Hold	100	–	–	﹤0.01%	3240
2023 Q2	$742	Buy	+100	New	+$851	﹤0.01%	3162
2022 Q3	–	Sell	-100	Closed	–	–	3225
2022 Q2	$0	Buy	+100	New	+$568	﹤0.01%	3236

Other funds holding ATNM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CFM

Compass Financial Management Tampa, Florida $829M AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Steward Partners Investment Advisory's ATNM Position: Q2 2026 in Review

Steward Partners Investment Advisory reduced its Actinium Pharmaceuticals (ATNM) stake by 7.7% in Q2 2026, selling an estimated $192 and leaving 2,000 shares worth $1.96K. The position accounts for ﹤0.01% of the portfolio, ranked #4242.

Steward Partners Investment Advisory first reported a position in ATNM in Q2 2022 and has held it in 13 quarters since. The position peaked at $3.76K in Q3 2024. 47 funds tracked by Wall St. Rank hold ATNM as of Q2 2026.

Steward Partners Investment Advisory held 2,000 shares of Actinium Pharmaceuticals worth $1.96K as of Q2 2026.
Steward Partners Investment Advisory sold 166 Actinium Pharmaceuticals shares in Q2 2026, an estimated $192.
Actinium Pharmaceuticals made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #4242 holding.
Steward Partners Investment Advisory first reported a position in Actinium Pharmaceuticals in Q2 2022 and has held it in 13 quarters since.
Steward Partners Investment Advisory's Actinium Pharmaceuticals position peaked at $3.76K in Q3 2024.
47 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.